Lupin receives USFDA approval for Mycophenolic Acid Delayed-Release Tablets
Lupin in alliance with Concord Biotech announced that it has received approval from the United States Food and Drug Administration (USFDA)
for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, to market the generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Dec 20 2019 | 3:37 PM IST